Uniqure NV Price, Forecast, Insider, Ratings, Fundamentals & Signals

~ presented promising clinical update from u.s. and european phase i/ii trials of amt-130 in huntington's disease; up to three years of follow-up data to be presented in mid-2024; regulatory interactions and clarity on potential strategies for clinical development expected in 2024 ~

~ patients treated with amt-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history  of the disease ~

Hemgenix® is the first and only gene therapy approved by the u.s. food and drug administration (fda) for the treatment of hemophilia b and to show sustained efficacy and safety at three years post-treatment long-term data continues to show a one-time infusion of hemgenix offers elevated and sustained factor ix activity levels for years and significantly reduces the rate of annual bleeds versus factor ix prophylaxis with a favorable safety profile at three years post-treatment with hemgenix, 94% of patients remained free of continuous prophylactic treatment king of prussia, pa. , dec. 11, 2023 /prnewswire/ -- global biotechnology leader csl (asx: csl; usotc: cslly) today announced the three-year results from the pivotal hope-b study confirming continued long-term durability and safety of hemgenix® (etranacogene dezaparvovec-drlb) following a one-time infusion in people living with hemophilia b.

Lexington, mass. and amsterdam, dec. 08, 2023 (globe newswire) -- uniqure n.v. (nasdaq: qure), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees.

Lexington, mass. and amsterdam, nov. 29, 2023 (globe newswire) -- uniqure n.v.

UniQure (QURE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to earnings of $0.15 per share a year ago.

Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and under-capitalized companies, but these companies also have unique theses that should keep investors interested.

UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.

uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.

uniQure said it is cutting back 28% of its workforce. The company is discontinuing much of its pipeline to focus on more promising therapies.

Gene therapy-focused biotechnology firm uniQure announced it is slashing more than half of its research and technology projects as part of a strategic reorganization aimed at reducing its operating expenses while advancing a selection of its clinical-stage programs to proof-of-concept.  The company said it will no longer be investing in AMT-210 for the treatment of Parkinson's disease and multiple other undisclosed programs.

UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its workforce as it strives to cut costs and advance several clinical-stage programs.

The Food and Drug Administration has cleared uniQure's application for an epilepsy therapy. The company grew revenue in the second quarter by 380%, year over year.

As a rule of thumb, you should avoid targeting cheap securities, However, exceptions can always be made, particularly for these tantalizing stocks under $10 to buy. To be sure, the cheap ideas in the capital market attract much attention.

UniQure (QURE) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of $2.97. This compares to loss of $0.84 per share a year ago.